Breztri Aerosphere is FDA-approved only for the maintenance treatment of COPD, not asthma. This isn’t because the inhaler is inherently dangerous for asthma patients. It’s because the drug was developed, tested, and brought to market for COPD first, and the diseases involve different types of inflammation that call for different treatment strategies. That said, the story is evolving: large clinical trials have recently tested Breztri in asthma with promising results.
What Breztri Contains and Why It Targets COPD
Breztri is a triple-therapy inhaler combining three active drugs: budesonide (an inhaled corticosteroid that reduces inflammation), glycopyrrolate (a long-acting anticholinergic that relaxes airway muscles), and formoterol (a long-acting bronchodilator that opens the airways). Each of these drug classes addresses a specific problem in COPD, where airway narrowing, excess mucus production, and chronic inflammation all contribute to breathing difficulty.
In COPD, the inflammation is primarily driven by immune cells called neutrophils and macrophages. Anticholinergics like glycopyrrolate are a cornerstone of COPD treatment because they counteract the nerve signals that cause airways to tighten, and they reduce mucus secretion. The combination of all three drug classes in a single inhaler has been shown in multiple studies to lower the rate of COPD flare-ups more effectively than using just one or two of these drug types.
Asthma and COPD Are Different Diseases
Although both conditions involve inflamed, narrowed airways, the underlying biology is quite different. In asthma, the dominant immune players are mast cells, eosinophils, and a specific type of immune cell called Th2 lymphocytes. These cells drive allergic-type inflammation that makes airways hypersensitive to triggers like pollen, cold air, or exercise. In COPD, the inflammation is less allergic in nature and more tied to long-term damage from irritants like cigarette smoke, with neutrophils and macrophages doing most of the work.
This distinction matters for treatment. Inhaled corticosteroids are the backbone of asthma management because they directly tamp down the eosinophilic, Th2-driven inflammation that causes asthma symptoms. In COPD, corticosteroids play a more limited role. They’re mainly used to reduce flare-ups rather than as the primary therapy. Because the diseases respond differently to the same drug classes, regulators require separate clinical trials proving that a medication works safely in each condition before granting approval.
The Historical Safety Concern With LABAs in Asthma
One important reason for caution involves formoterol, Breztri’s long-acting bronchodilator component. In the early 2000s, a large safety study found that a related drug, salmeterol, was associated with a fourfold increase in asthma-related deaths when added to usual asthma therapy (13 deaths among roughly 13,000 patients on salmeterol versus 3 deaths among 13,000 on placebo). The FDA treated this as a potential class-wide risk for all long-acting bronchodilators, including formoterol.
This led to boxed warnings on LABA-containing inhalers stating they should not be used for asthma without an accompanying corticosteroid. Breztri does contain a corticosteroid (budesonide), which addresses that specific concern. But the historical caution meant that any LABA-containing product needed rigorous asthma-specific safety and efficacy data before the FDA would approve it for that use. Clinical studies with inhaled formoterol also suggested a higher incidence of serious asthma flare-ups compared to placebo, adding to the regulatory hesitancy.
Clinical Trials in Asthma Are Now Complete
Breztri’s manufacturer has actually been pursuing asthma approval. Two large phase 3 trials, called KALOS and LOGOS, enrolled over 8,800 participants aged 12 to 80 across hundreds of sites in dozens of countries. These studies tested Breztri in people whose asthma remained poorly controlled despite using medium- or high-dose inhaled corticosteroid/LABA combinations.
The results, published in The Lancet Respiratory Medicine in 2025, were positive. Breztri improved lung function compared to standard two-drug inhalers, with patients gaining an average of 76 mL improvement in a key measure of airflow. It also reduced the rate of severe asthma flare-ups by 14% to 18% depending on the comparison group. Adverse event rates were similar across all treatment arms, and no deaths were related to the treatment. The researchers concluded that Breztri improves lung function and reduces severe flare-ups in people with inadequately controlled asthma.
These trials met all of their primary endpoints, which is typically what the FDA requires to consider a new approval. So while Breztri is not currently approved for asthma, that may change in the near future.
Why You Can’t Just Substitute a COPD Inhaler for Asthma
Using a COPD-specific inhaler for asthma without proper clinical guidance creates real risks. The dosing, delivery, and drug ratios in COPD formulations are optimized for a different disease. Corticosteroids in COPD inhalers, for instance, can suppress parts of the immune system that protect against respiratory infections. Research has established a clear link between inhaled corticosteroid use in COPD and increased pneumonia risk, partly because these drugs can impair the body’s ability to fight off bacteria after a viral infection. The immune trade-offs are different in asthma, where corticosteroids are more clearly beneficial and the pneumonia risk is lower.
There’s also the issue of incomplete treatment. Asthma management follows a stepwise approach built around specific drug combinations that have been validated for the condition. Skipping that framework by borrowing a COPD inhaler could mean undertreating the allergic inflammation that drives asthma while adding a drug (the anticholinergic) that, while not harmful, may not be addressing your primary problem. Anticholinergics do produce some bronchodilation in asthma, but they aren’t first-line therapy the way they are in COPD.
Other Triple Therapies Approved for Asthma
If you need triple therapy for asthma, options do exist. Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) is another triple-combination inhaler that has been studied and approved for both COPD and asthma. It contains the same three drug classes as Breztri but uses different specific compounds and a different inhaler device. The key difference is simply that Trelegy completed asthma-specific trials and received FDA approval for that indication earlier than Breztri.
For now, Breztri’s label restricts its use to COPD. That restriction reflects the regulatory timeline rather than evidence that the drug is dangerous for asthma. The recent trial data suggests approval for asthma could follow, but until then, the FDA has not reviewed and authorized that use.